Skip to main content
. 2020 Apr 2;9(4):296. doi: 10.3390/antiox9040296

Figure 3.

Figure 3

PCSK9 and platelet activation. Platelet aggregation (A) with relative representative tracing (B) and platelet TxB2 (C) evaluated in platelet rich plasma (PRP) treated with PCSK9 (1 and 2 ng/mL) and stimulated with subthreshold concentration (STC) of collagen (0.25 μg/mL) in presence or not of anti-CD36, anti-LOX1, Nox2ds-tat and anti-PCSK9. (n = 5) (*p < 0.05, **p < 0.001 for paired analyses).